BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34398070)

  • 1. Emerging Treatment Strategies in Pancreatic Cancer.
    Trunk A; Miotke L; Nevala-Plagemann C; Verdaguer H; Macarulla T; Garrido-Laguna I
    Pancreas; 2021 Jul; 50(6):773-787. PubMed ID: 34398070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
    Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
    J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opportunities for translation: targeting DNA repair pathways in pancreatic cancer.
    Maginn EN; de Sousa CH; Wasan HS; Stronach EA
    Biochim Biophys Acta; 2014 Aug; 1846(1):45-54. PubMed ID: 24727386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma.
    Zhen DB; Coveler A; Zanon S; Reni M; Chiorean EG
    Semin Oncol; 2018 Jun; 45(3):107-115. PubMed ID: 30391013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perspectives in the treatment of pancreatic adenocarcinoma.
    Cid-Arregui A; Juarez V
    World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pancreas cancer: Therapeutic trials in metastatic disease.
    Smithy JW; O'Reilly EM
    J Surg Oncol; 2021 May; 123(6):1475-1488. PubMed ID: 33831245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Therapeutics for Pancreatic Adenocarcinoma.
    Lowery MA; O'Reilly EM
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):777-87. PubMed ID: 26226910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pancreatic cancer subtypes: a roadmap for precision medicine.
    Torres C; Grippo PJ
    Ann Med; 2018 Jun; 50(4):277-287. PubMed ID: 29537309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in Systemic Therapy in Pancreatic Cancer.
    Yu KH
    Hematol Oncol Clin North Am; 2024 Jun; 38(3):617-627. PubMed ID: 38575456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
    Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
    Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia and pancreatic ductal adenocarcinoma.
    Yamasaki A; Yanai K; Onishi H
    Cancer Lett; 2020 Aug; 484():9-15. PubMed ID: 32380129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels.
    Du J; Gu J; Li J
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32677676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications.
    Hu HF; Ye Z; Qin Y; Xu XW; Yu XJ; Zhuo QF; Ji SR
    Acta Pharmacol Sin; 2021 Nov; 42(11):1725-1741. PubMed ID: 33574569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality?
    Krantz BA; O'Reilly EM
    Clin Cancer Res; 2018 May; 24(10):2241-2250. PubMed ID: 29269376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on the management of pancreatic cancer: surgery is not enough.
    Ansari D; Gustafsson A; Andersson R
    World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
    Muth ST; Saung MT; Blair AB; Henderson MG; Thomas DL; Zheng L
    Cancer Lett; 2021 Feb; 499():99-108. PubMed ID: 33271264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diverse and precision therapies open new horizons for patients with advanced pancreatic ductal adenocarcinoma.
    Bai RL; Wang NY; Zhao LL; Zhang YF; Cui JW
    Hepatobiliary Pancreat Dis Int; 2022 Feb; 21(1):10-24. PubMed ID: 34538570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies.
    Adamska A; Domenichini A; Falasca M
    Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28640192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New targeted therapies in pancreatic cancer.
    Seicean A; Petrusel L; Seicean R
    World J Gastroenterol; 2015 May; 21(20):6127-45. PubMed ID: 26034349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma.
    Singh RR; O'Reilly EM
    Drugs; 2020 May; 80(7):647-669. PubMed ID: 32306207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.